The Polo Tecnologico Piemontese opens in Candiolo (Turin)

It will be inaugurated in autumn, it will be an incubator for innovative companies, a center that will host cutting-edge technological companies and research institutes and which sees the HBW Group as the leader of the group 13-Jul-2021 9:00 AM EDT, by Sbarro Health Research Organization (SHRO)1favorite_border The project is part of a broader framework of the … Continue reading The Polo Tecnologico Piemontese opens in Candiolo (Turin)

Researchers Explore Potential Biomarker for Rare Gynecological Cancers in Long Non-Coding RNAs

Long Non-Coding RNAs (lncRNAs) are detectable in body fluids, such as the blood, saliva, and urine, and are therefore emerging as a novel method for cancer diagnosis, but few studies have explored the link between lncRNAs and choriocarcinoma (CC), a rare but serious type of cancer affecting the female reproductive organs. Because CC is important … Continue reading Researchers Explore Potential Biomarker for Rare Gynecological Cancers in Long Non-Coding RNAs

The Medicine in Eye Drops Needs a Disguise to Sneak Past Your Tears

Scientists use engineered protein coating that binds to receptors on the surface of corneal cells to improve drug uptake. The most practical solution for drug delivery to the eyeball is topical, i.e. eye drops. However, a naturally occurring substance in tears actually can interact with the drug delivery system (DDS), hindering absorption of the drug … Continue reading The Medicine in Eye Drops Needs a Disguise to Sneak Past Your Tears

Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment

In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the blood as a response to bacterial infection, both predict a poor response to treatment with immune checkpoint blockade.  The novel treatment studied includes peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab), or PD-L1 … Continue reading Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment

SHRO’s Giordano Meets with Speaker Pelosi at Italian Embassy in Washington

Newswise — WASHINGTON, D.C. May 19, 2021—At the prestigious setting of Villa Firenze, the Italian Embassy in Washington, DC, on the occasion of a farewell party for outgoing Ambassador Armando Varricchio, Professor Antonio Giordano, Neapolitan oncologist, director of the Sbarro Institute for Cancer Research at Temple University, member of the board of directors of the … Continue reading SHRO’s Giordano Meets with Speaker Pelosi at Italian Embassy in Washington

Researchers Call for More Transparency from Russia’s Sputnik COVID Vaccine

“It is not a problem connected to “the Sputnik V” vaccine itself,” argues Prof. Enrico Bucci, adjunct professor in the Department of Biology, Temple University, and senior staff member of the Sbarro Health Research Organization (SHRO). “It is a problem connected to the way results are documented, data are provided, and scientific journals react to … Continue reading Researchers Call for More Transparency from Russia’s Sputnik COVID Vaccine

Like Asbestos, Do Carbon Nanotubes Have Potential Health Risks?

 A new study examines the recent literature on carbon nanotubes toxicity highlighting their strong inflammatory potential for the respiratory system. The Carbon nanotubes are the most promising type of nano-materials used in the field of nanotechnology for applications in medicine, sporting goods, automotive parts and water filters, among others. The similarities in physico-chemical characteristics between … Continue reading Like Asbestos, Do Carbon Nanotubes Have Potential Health Risks?

Precision Medicine and the Anti-Cancer Properties of Foods like Green Tea, SHRO Founder Comments

Prof. Antonio Giordano available to comment on recently published research from Rensselaer Polytechnic Institute (RPI)  Green Tea Compound Aids Tumor-Suppressing, DNA-Repairing ProteinAn antioxidant found in green tea may increase levels of p53, a natural anti-cancer protein, known as the “guardian of the genome” for its ability to repair DNA damage or destroy cancerous cells. Published today … Continue reading Precision Medicine and the Anti-Cancer Properties of Foods like Green Tea, SHRO Founder Comments

SHRO Founder Leads Search for Fauci Fellows

The National Italian American Foundation (NIAF) is now accepting applications for the inaugural class of Fauci Fellowships, created in recognition of Dr. Anthony S. Fauci’s contributions to humanity and the medical and scientific community. Antonio Giordano, M.D., Ph.D., Director and Professor, Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, serves on the … Continue reading SHRO Founder Leads Search for Fauci Fellows

International Research Collaboration to Address Delayed Diagnosis of Rare Gynecological Cancers

Sbarro Health Research Organization (SHRO) Founder and Director, Antonio Giordano, M.D., Ph.D., has recently published a landmark paper in collaboration with another 28 co-authors hailing from 14 different countries, as part of the GYNOCARE COST Action (CA18117). GYNOCARE is a European Network for Gynaecological Rare Cancer research: From Concept to Cure, which is chaired by … Continue reading International Research Collaboration to Address Delayed Diagnosis of Rare Gynecological Cancers